MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41598-021-90797-0

Медицинская библиотека · Scientific reports · 2021

Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19.

Julià Antonio, Bonafonte-Pardàs Irene, Gómez Antonio, López-Lasanta María, López-Corbeto Mireia, Martínez-Mateu Sergio H, Lladós Jordi, Rodríguez-Nunez Iván, Myers Richard M, Marsal Sara

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

An excessive immune response known as cytokine storm is the hallmark of severe COVID-19. The cause of this cytokine rampage is yet not known. Based on recent epidemiological evidence, we hypothesized that CD80/86 signaling is essential for this hyperinflammation, and that blocking this proinflammatory axis could be an effective therapeutic approach to protect against severe COVID-19. Here we provide exploratory evidence that abatacept, a drug that blocks CD80/86 co-stimulation, produces changes at the systemic level that are highly antagonistic of the proinflammatory processes elicited by COVID-19. Using RNA-seq from blood samples from a longitudinal cohort of n = 38 rheumatic patients treated with abatacept, we determined the immunological processes that are significantly regulated by this treatment. We then analyzed available blood RNA-seq from two COVID19 patient cohorts, a very early cohort from the epicenter of the pandemic in China (n = 3 COVID-19 cases and n = 3 controls), and a recent and larger cohort from the USA (n = 49 severe and n = 51 mild COVD-19 patients). We found a highly significant antagonism between SARS-CoV-2 infection and COVID-19 severity with the systemic response to abatacept. Analysis of previous single-cell RNA-seq data from bronchoalveolar lavage fluid from mild and severe COVID-19 patients and controls, reinforce the implication of the CD80/86 proinflammatory axis. Our functional results further support abatacept as a candidate therapeutic approach to prevent severe COVID-19.

Для цитирования: Julià Antonio, Bonafonte-Pardàs Irene, Gómez Antonio, López-Lasanta María, López-Corbeto Mireia, Martínez-Mateu Sergio H, Lladós Jordi, Rodríguez-Nunez Iván, Myers Richard M, Marsal Sara. Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19.. Scientific reports. 2021. DOI: 10.1038/s41598-021-90797-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.